Recommendations of the Polish Group of Experts for HCV for the Treatment of Hepatitis C in 2020

Overview

Journal Clin Exp Hepatol

Specialty Gastroenterology

Date 2020 Nov 4

PMID 33145422

Citations 15

Authors

Waldemar Halota

Robert Flisiak

Jacek Juszczyk

Piotr Malkowski

Malgorzata Pawlowska

Krzysztof Simon

Krzysztof Tomasiewicz

Affiliations

Soon will be listed here.

Abstract

The recommendations set out the principles of diagnosis and treatment of hepatitis C virus (HCV) infections according to the most recent knowledge. The main goal of therapy for HCV infection is to eliminate the virus from the body, which consequently leads to arrest of progress or regression of changes in the liver. Current version of the recommendations prioritise pangenotypic regimens and provide guidelines in special populations of patients, such as children, cirrhotics, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfected, those with renal failure, hepatic decompensation and non-responders to previous therapies.

Citing Articles

Treatment of HCV infection in patients with steatotic liver disease.

Flisiak R, Zarebska-Michaluk D, Dobrowolska K, Janocha-Litwin J, Dybowska D, Sitko M Clin Exp Hepatol. 2024; 10(3):159-164.

PMID: 39697371 PMC: 11650810. DOI: 10.5114/ceh.2024.141699.

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination.

Zarebska-Michaluk D, Brzdek M, Tronina O, Janocha-Litwin J, Sitko M, Piekarska A BMC Med. 2024; 22(1):486.

PMID: 39444018 PMC: 11515622. DOI: 10.1186/s12916-024-03699-z.

Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices.

Brzdek M, Zarebska-Michaluk D, Kukla M, Janocha-Litwin J, Dybowska D, Janczewska E Pharmacol Rep. 2024; 76(5):1114-1129.

PMID: 39162985 PMC: 11387439. DOI: 10.1007/s43440-024-00639-9.

Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure.

Tronina O, Brzdek M, Zarebska-Michaluk D, Lorenc B, Janocha-Litwin J, Berak H Clin Exp Hepatol. 2024; 9(4):320-334.

PMID: 38774196 PMC: 11103803. DOI: 10.5114/ceh.2023.133307.

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C-Results of a Multicenter EpiTer-2 Study.

Pawlowska M, Dobrowolska K, Moppert J, Pokorska-Spiewak M, Purzynska M, Marczynska M J Clin Med. 2023; 12(21).

PMID: 37959413 PMC: 10647729. DOI: 10.3390/jcm12216949.

References

Cornberg M, Petersen J, Schober A, Mauss S, Boker K, Link R . Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2017; 45(5):688-700. DOI: 10.1111/apt.13925. View

Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T . Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant. 2015; 15(5):1313-22. PMC: 5024008. DOI: 10.1111/ajt.13111. View

Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A . High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Aliment Pharmacol Ther. 2018; 47(12):1705-1712. DOI: 10.1111/apt.14685. View

Bersoff-Matcha S, Cao K, Jason M, Ajao A, Jones S, Meyer T . Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017; 166(11):792-798. DOI: 10.7326/M17-0377. View

Gadiparthi C, Cholankeril G, Perumpail B, Yoo E, Satapathy S, Nair S . Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol. 2018; 24(3):315-322. PMC: 5776393. DOI: 10.3748/wjg.v24.i3.315. View

. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2016; 66(1):153-194. DOI: 10.1016/j.jhep.2016.09.001. View

Nault J, Colombo M . Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. 2016; 65(4):663-665. DOI: 10.1016/j.jhep.2016.07.004. View

Zarebska-Michaluk D, Flisiak R, Jaroszewicz J, Janczewska E, Czauz-Andrzejuk A, Berak H . Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?. J Interferon Cytokine Res. 2018; 38(2):93-100. DOI: 10.1089/jir.2017.0113. View

Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N . Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2017; 66(3):505-515. DOI: 10.1097/MPG.0000000000001872. View

10.

Flisiak R, Lucejko M, Mazur W, Janczewska E, Berak H, Tomasiewicz K . Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. Adv Med Sci. 2017; 62(2):387-392. DOI: 10.1016/j.advms.2017.04.004. View

11.

Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarebska-Michaluk D, Nazzal K . Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016; 44(9):946-956. DOI: 10.1111/apt.13790. View

12.

Walewska-Zielecka B, Religioni U, Juszczyk G, Wawrzyniak Z, Czerw A, Soszynski P . Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014. Euro Surveill. 2017; 22(2). PMC: 5404489. DOI: 10.2807/1560-7917.ES.2017.22.2.30441. View

13.

Flisiak R, Flisiak-Jackiewicz M . Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C. Expert Rev Gastroenterol Hepatol. 2017; 11(6):559-567. DOI: 10.1080/17474124.2017.1309284. View

14.

. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016; 65(4):734-740. DOI: 10.1016/j.jhep.2016.05.045. View

15.

Mucke M, Backus L, Mucke V, Coppola N, Preda C, Yeh M . Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018; 3(3):172-180. DOI: 10.1016/S2468-1253(18)30002-5. View

16.

Saab S, Jimenez M, Fong T, Wu C, Kabany M, Tong M . Timing of Antiviral Therapy in Candidates for Liver Transplant for Hepatitis C and Hepatocellular Carcinoma. Exp Clin Transplant. 2015; 14(1):66-71. DOI: 10.6002/ect.2015.0069. View

17.

Flisiak R, Halota W, Horban A, Juszczyk J, Pawlowska M, Simon K . Prevalence and risk factors of HCV infection in Poland. Eur J Gastroenterol Hepatol. 2011; 23(12):1213-7. DOI: 10.1097/MEG.0b013e32834d173c. View

18.

Zarebska-Michaluk D, Flisiak R, Flisiak-Jackiewicz M . Management of hepatitis B and hepatitis C coinfection: an expert review. Expert Rev Anti Infect Ther. 2020; 18(10):1033-1044. DOI: 10.1080/14787210.2020.1776112. View

19.

Jaroszewicz J, Pawlowska M, Simon K, Zarebska-Michaluk D, Lorenc B, Klapaczynski J . Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA. Expert Rev Anti Infect Ther. 2020; 18(10):1045-1054. DOI: 10.1080/14787210.2020.1782189. View

20.

Ghany M, Morgan T . Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2019; 71(2):686-721. PMC: 9710295. DOI: 10.1002/hep.31060. View